These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 35930737)
1. Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Ning S; Liu C; Lou W; Yang JC; Lombard AP; D'Abronzo LS; Batra N; Yu AM; Leslie AR; Sharifi M; Evans CP; Gao AC Mol Cancer Ther; 2022 Oct; 21(10):1594-1607. PubMed ID: 35930737 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer. Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338 [TBL] [Abstract][Full Text] [Related]
3. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193 [TBL] [Abstract][Full Text] [Related]
4. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. Armstrong CM; Liu C; Liu L; Yang JC; Lou W; Zhao R; Ning S; Lombard AP; Zhao J; D'Abronzo LS; Evans CP; Li PK; Gao AC Clin Cancer Res; 2020 Nov; 26(22):6064-6074. PubMed ID: 32928794 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Nakazawa M; Antonarakis ES; Luo J Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254 [TBL] [Abstract][Full Text] [Related]
6. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814 [TBL] [Abstract][Full Text] [Related]
7. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer. Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858 [TBL] [Abstract][Full Text] [Related]
9. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Miyamoto DT; Zheng Y; Wittner BS; Lee RJ; Zhu H; Broderick KT; Desai R; Fox DB; Brannigan BW; Trautwein J; Arora KS; Desai N; Dahl DM; Sequist LV; Smith MR; Kapur R; Wu CL; Shioda T; Ramaswamy S; Ting DT; Toner M; Maheswaran S; Haber DA Science; 2015 Sep; 349(6254):1351-6. PubMed ID: 26383955 [TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones. Leung JK; Tam T; Wang J; Sadar MD Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481 [TBL] [Abstract][Full Text] [Related]
11. Activation of β-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer. Patel R; Brzezinska EA; Repiscak P; Ahmad I; Mui E; Gao M; Blomme A; Harle V; Tan EH; Malviya G; Mrowinska A; Loveridge CJ; Rushworth LK; Edwards J; Ntala C; Nixon C; Hedley A; Mackay G; Tardito S; Sansom OJ; Leung HY Cancer Res; 2020 Feb; 80(3):576-590. PubMed ID: 31719098 [TBL] [Abstract][Full Text] [Related]
12. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226 [TBL] [Abstract][Full Text] [Related]
13. ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature. Vellky JE; Kirkpatrick BJ; Gutgesell LC; Morales M; Brown RM; Wu Y; Maienschein-Cline M; Notardonato LD; Weinfeld MS; Nguyen RH; Brister E; Sverdlov M; Liu L; Xu Z; Kregel S; Nonn L; Vander Griend DJ; Reizine NM Clin Cancer Res; 2024 Apr; 30(8):1530-1543. PubMed ID: 38306015 [TBL] [Abstract][Full Text] [Related]
14. Downregulation of Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112 [TBL] [Abstract][Full Text] [Related]
15. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer. Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366 [TBL] [Abstract][Full Text] [Related]
17. Role of solute carrier transporters SLC25A17 and SLC27A6 in acquired resistance to enzalutamide in castration-resistant prostate cancer. Kushwaha PP; Verma SS; Shankar E; Lin S; Gupta S Mol Carcinog; 2022 Apr; 61(4):397-407. PubMed ID: 34939235 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer. Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC). Kong Y; Cheng L; Mao F; Zhang Z; Zhang Y; Farah E; Bosler J; Bai Y; Ahmad N; Kuang S; Li L; Liu X J Biol Chem; 2018 Sep; 293(37):14328-14341. PubMed ID: 30089652 [TBL] [Abstract][Full Text] [Related]
20. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]